IVA — Inventiva SA Share News
0.000.00%
Last trade - 00:00- €669.85m
- €502.00m
- €4.48m
Brief: Inventiva Reports 2024 First Quarter Financial Information
Brief: Inventiva SA Says DMC Review Confirms Good Safety Profile Of Lanifibranor
Brief: Inventiva SA Revenues At EUR 17.5 Million For Full Year Of 2023
Brief: Inventiva Announces Positive Results From Phase II Legend Study
Brief: Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin
Brief: Inventiva Draws Down The Second Tranche Of €25 Mln Under Existing Finance Contract With The European Investment Bank
Brief: Inventiva Randomizes First Patient In Nativ3 Clinical Trial In China
Brief: Inventiva Announces Positive Recommendation Phase III Clinical Trial With Lanifibranor In Patients With Nash
Brief: Inventiva Announces Positive Recommendation Of The Third DMC Of The Phase III Clinical Trial With Lanifibranor In Patients With Nash
Brief: Inventiva 9M Revenue Up At Eur 1.9 Mln
Brief: Inventiva And Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement To Develop And Commercialize Lanifibranor In Japan And South Korea
Brief: Inventiva And Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement To Develop And Commercialize Lanifibranor In Japan And South Korea
'Undervalued' Inventiva jumps after KBC ups to buy
Brief: Inventiva Announces Financing Of About EUR 35.7 Million From New And Existing Investors
Brief: Inventiva Says Revenues For First Half Of 2023 Amounted To EUR 1.9 Million Vs EUR 0.1 Million
Europe Research Roundup: Boliden AB, Fortum Oyj, Schibsted ASA
Inventiva soars on positive trial data for lanifibranor
Brief: Inventiva Announces Positive Topline Results From Investigator-Initiated Phase II Clinical Trial Evaluating Lanifibranor
Brief: Inventiva Announces Positive Topline Results From The Investigator-Initiated Phase II Clinical Trial Evaluating Lanifibranor In Patients With T2D And NAFLD